Autonomic Testing
Autonomic testing is the systematic evaluation of the sympathetic, parasympathetic, and sudomotor divisions of the autonomic nervous system using standardized, validated physiologic protocols. The autonomic reflex screen, combined with sudomotor testing, provides a comprehensive functional assessment that quantifies the severity, distribution, and localization (central versus peripheral, preganglionic versus postganglionic) of autonomic dysfunction. These tests are essential for diagnosing autonomic disorders, differentiating between etiologies that have vastly different prognoses and treatment implications, and monitoring disease progression or response to therapy. The Composite Autonomic Severity Score (CASS) integrates results across all three domains into a standardized severity grading system that facilitates clinical communication and research comparisons.
Bottom Line
- Three test domains: Cardiovagal (heart rate variability, Valsalva ratio), adrenergic (tilt table BP, beat-to-beat Valsalva BP phases, plasma catecholamines), and sudomotor (QSART, thermoregulatory sweat test)
- CASS scoring: Composite Autonomic Severity Score grades each domain (cardiovagal 0–3, adrenergic 0–4, sudomotor 0–3, total 0–10) for standardized severity quantification
- Key localizing principle: TST + QSART both abnormal = postganglionic lesion; TST abnormal + QSART normal = preganglionic lesion
- Plasma catecholamines: Low supine NE = peripheral lesion (PAF, PD); normal supine NE with failure to rise = central lesion (MSA)
- Additional tools: Skin biopsy (IENFD for small fiber neuropathy), cardiac MIBG scintigraphy (postganglionic cardiac sympathetic innervation), pupillometry
- Clinical integration: Test results must always be interpreted in context of clinical history, medication effects, and comorbidities
Cardiovagal Testing
Cardiovagal tests evaluate the integrity of the parasympathetic (vagal) innervation to the heart by measuring heart rate variability in response to standardized physiologic stimuli. Cardiovagal dysfunction is one of the earliest detectable autonomic abnormalities in many neuropathies.
Heart Rate Response to Deep Breathing (HRDB)
The heart rate response to deep breathing is the most sensitive and reproducible test of cardiovagal function. It measures the physiologic respiratory sinus arrhythmia — heart rate increases during inspiration (reduced vagal tone) and decreases during expiration (increased vagal tone).
- Protocol: Patient breathes deeply at a controlled rate of 6 breaths per minute (5 seconds in, 5 seconds out) for 1 minute while supine; ECG continuously records R-R intervals
- Measurement: Maximum heart rate during inspiration minus minimum heart rate during expiration, averaged across all breathing cycles
- Normal values: Age-dependent (decline with age); generally ≥15 bpm in young adults, ≥9 bpm in patients over 60
- Abnormal: Reduced HRDB indicates cardiovagal (parasympathetic) neuropathy; one of the earliest autonomic abnormalities in diabetic autonomic neuropathy
- Confounders: Medications (beta-blockers, anticholinergics), age, breathing rate and depth, obesity, low baseline heart rate
Clinical Significance of HRDB
- Most sensitive single test for early cardiovagal dysfunction
- Reduced HRDB is a marker of cardiovascular autonomic neuropathy (CAN) in diabetes and confers increased mortality risk
- Early abnormality in neuropathic POTS, AAG, diabetic neuropathy, and amyloid neuropathy
- Normal HRDB effectively excludes significant cardiovagal impairment
- Can be performed at bedside with minimal equipment (ECG + timer)
Valsalva Maneuver
The Valsalva maneuver is a complex cardiopulmonary challenge that evaluates both sympathetic (adrenergic) and parasympathetic (cardiovagal) pathways through four distinct hemodynamic phases.
Protocol
- Patient blows into a mouthpiece maintaining 40 mmHg of expiratory pressure for 15 seconds, then releases
- Continuous beat-to-beat blood pressure (finger plethysmography) and ECG are recorded
- Both heart rate changes and blood pressure changes across all four phases are analyzed
Four Phases of the Valsalva Maneuver
| Phase | Timing | Normal Response | Autonomic Pathway Tested | Abnormal in Autonomic Failure |
|---|---|---|---|---|
| Phase I | Onset of strain | Transient BP rise (mechanical compression of aorta) | Mechanical — not autonomic | Usually preserved |
| Early Phase II | Continued strain (first 5–7 seconds) | BP falls as venous return decreases; HR rises (reflex tachycardia via baroreflex) | Cardiovagal withdrawal + sympathetic activation | Progressive BP fall without recovery; absent reflex tachycardia in cardiovagal failure |
| Late Phase II | Continued strain (last 5–8 seconds) | BP begins to recover toward baseline (sympathetic vasoconstriction restores vascular tone) | Adrenergic (sympathetic vasoconstriction) | Absent late phase II recovery — hallmark of adrenergic failure; BP continues to fall throughout strain |
| Phase III | Release of strain | Transient BP drop (mechanical — release of intrathoracic pressure) | Mechanical — not autonomic | Usually preserved |
| Phase IV | 10–30 seconds after release | Blood pressure overshoot above baseline + reflex bradycardia (baroreflex-mediated) | Adrenergic (overshoot) + cardiovagal (bradycardia) | Absent phase IV overshoot and bradycardia — adrenergic failure; no overshoot = failed vasoconstriction during strain |
Valsalva Ratio
- Calculation: Maximum heart rate during phase II (strain) divided by minimum heart rate during phase IV (post-strain bradycardia)
- Normal: ≥1.4 in young adults (age-dependent norms; decreases with age)
- Reduced Valsalva ratio: Indicates cardiovagal dysfunction (impaired reflex bradycardia)
- Interpretation requires beat-to-beat BP data: HR changes alone are insufficient; BP waveform analysis is essential for adrenergic interpretation
30:15 Ratio (Standing)
- Measurement: Ratio of the R-R interval at beat 30 after standing to the R-R interval at beat 15
- Normal: ≥1.04 (reflects initial reflex tachycardia followed by compensatory bradycardia)
- Reduced 30:15 ratio: Indicates cardiovagal impairment; less sensitive than HRDB
- Primarily a cardiovagal test: Evaluates the baroreflex-mediated heart rate response to the initial blood pressure drop on standing
Adrenergic Testing
Adrenergic (sympathetic) testing evaluates the ability of the sympathetic nervous system to maintain blood pressure during postural stress and the Valsalva maneuver. These tests are critical for diagnosing orthostatic hypotension and quantifying the severity of adrenergic failure.
Tilt Table Testing
- Protocol: Patient rests supine for 5–10 minutes, then tilted head-up to 60–70 degrees for up to 45 minutes
- Monitoring: Continuous beat-to-beat BP (finger plethysmography) and ECG; BP cuff confirmation at regular intervals
- Advantages over bedside orthostatics: Eliminates muscle pump artifact (passive tilt); continuous monitoring detects delayed OH; standardized and reproducible
| Finding on Tilt Table | BP Pattern | HR Pattern | Diagnosis |
|---|---|---|---|
| Neurogenic OH | SBP drop ≥20 mmHg or DBP drop ≥10 mmHg within 3 min; progressive decline | Blunted HR increase (<10–15 bpm) — absent compensatory tachycardia | Autonomic failure (MSA, PD, PAF, diabetic, amyloid) |
| Non-neurogenic OH | SBP drop ≥20 mmHg; often with volume depletion features | Appropriate tachycardia (≥15–20 bpm increase); reflex intact | Dehydration, hemorrhage, medications, adrenal insufficiency |
| POTS | SBP drop <20 mmHg (no significant OH) | HR increase ≥30 bpm (or ≥40 bpm in ages 12–19), or HR >120 bpm, sustained | Postural tachycardia syndrome |
| Vasovagal (neurocardiogenic) syncope | Sudden BP drop (often precipitous) after period of normal standing; typically at 10–45 min | Sudden bradycardia (cardioinhibitory), or HR may remain elevated (vasodepressor type), or mixed | Reflex (neurally-mediated) syncope; intact autonomic reflexes with paradoxical trigger |
| Delayed OH | BP drop meeting OH criteria only after >3 minutes (often at 5–10+ minutes) | Variable; may show progressive HR rise | Milder or early adrenergic dysfunction; may progress to classic OH over time |
| Initial OH | Transient SBP drop ≥40 mmHg within 15 seconds of standing (active standing test only — not tilt) | Transient tachycardia | Benign; exaggerated normal response; resolves spontaneously within 30–60 seconds |
Beat-to-Beat Blood Pressure During Valsalva
- Analysis of the Valsalva BP waveform (phases I–IV) provides the most sensitive measure of adrenergic function
- Absent late phase II recovery: The earliest and most sensitive indicator of sympathetic adrenergic failure; BP continues to decline throughout strain instead of recovering
- Absent phase IV overshoot: Confirms adrenergic failure; normally BP rises 10–30 mmHg above baseline after strain release
- Pressure recovery time (PRT): Time from Valsalva release to return to baseline SBP; prolonged in adrenergic failure
- Adrenergic baroreflex sensitivity: Slope of the relationship between BP changes and HR changes during Valsalva; reduced in baroreflex failure
Plasma Catecholamines (Supine and Standing)
| Measurement | Normal | Peripheral Autonomic Failure (PAF, PD) | Central Autonomic Failure (MSA) |
|---|---|---|---|
| Supine norepinephrine | 100–400 pg/mL | Low (<100 pg/mL) — postganglionic neuron loss depletes NE stores | Normal or mildly reduced (postganglionic neurons intact) |
| Standing norepinephrine | ≥2-fold increase from supine | Fails to rise appropriately (<2-fold) — too few surviving neurons | Fails to rise (<2-fold) — central command to release NE is impaired |
| Clinical utility | — | Distinguishes PAF (peripheral) from MSA (central); guides prognosis and phenoconversion prediction | Normal supine NE with standing failure helps confirm preganglionic (central) localization |
Catecholamine Testing Pitfalls
- Medications: Sympathomimetics (midodrine, droxidopa), MAO inhibitors, tricyclics, SNRIs, and stimulants can alter NE levels; ideally withhold for ≥5 half-lives before testing
- Patient positioning: Must be truly supine for ≥20–30 minutes before supine draw; standing sample after 5–10 minutes upright
- Sample handling: NE is labile; samples must be placed on ice immediately and processed within 30 minutes
- Context is essential: Normal supine NE does not exclude adrenergic failure; the standing response is equally important
Sudomotor Testing
Sudomotor testing evaluates the sympathetic cholinergic postganglionic fibers that innervate eccrine sweat glands. Because these small unmyelinated C fibers are among the first affected in length-dependent neuropathies, sudomotor testing is highly sensitive for detecting early autonomic involvement, particularly small fiber neuropathy.
Quantitative Sudomotor Axon Reflex Test (QSART)
- Principle: Acetylcholine iontophoresed into the skin activates local sudomotor axon terminals; the axon reflex causes sweat release at a nearby recording site via antidromic-orthodromic transmission
- Sites: Standardly recorded at 4 sites: forearm, proximal leg (medial thigh), distal leg (medial calf), and foot (dorsum)
- Output: Total sweat volume (in microliters) over 5 minutes at each site; compared to age- and sex-matched normative values
- Interpretation:
- Reduced sweat output: Postganglionic sudomotor axon dysfunction (small fiber neuropathy, diabetic neuropathy, PAF, PD)
- Length-dependent pattern: Distal sites (foot, distal leg) affected first and most severely; consistent with length-dependent neuropathy
- Excessive sweating (persistent sweat activity): May indicate denervation hypersensitivity or compensatory hyperhidrosis
- Sensitivity: Among the most sensitive tests for small fiber neuropathy; abnormal in ~50% of patients with neuropathic POTS
Thermoregulatory Sweat Test (TST)
- Principle: Patient is placed in a heated, humidified chamber (ambient temperature raised to 45–50°C); body surface is coated with an indicator powder (alizarin red or cornstarch-iodine) that changes color when wet with sweat
- Output: Whole-body topographic map of sweating versus anhidrosis; percentage of body surface area with anhidrosis is calculated
- Interpretation:
- Length-dependent anhidrosis: Distal-to-proximal gradient of sweat loss; consistent with peripheral neuropathy
- Global anhidrosis: Widespread sweat failure; seen in severe autonomic failure (PAF, MSA, severe diabetic neuropathy, AAG)
- Segmental or dermatomal: Suggests central or preganglionic lesion (spinal cord, sympathetic chain)
- Patchy or asymmetric: May indicate specific ganglion or nerve involvement
TST + QSART: The Localizing Combination
- TST abnormal + QSART abnormal = Postganglionic lesion: Both the central command (TST triggers sweating via the full pathway) and the local axon reflex (QSART) are impaired because the postganglionic neuron itself is damaged. Seen in: PAF, PD, small fiber neuropathy, diabetic neuropathy
- TST abnormal + QSART normal = Preganglionic lesion: The central command pathway (hypothalamus → spinal cord → preganglionic sympathetic neuron) is disrupted, but the postganglionic neuron is intact and can still respond to local chemical stimulation (QSART). Seen in: MSA, spinal cord lesions, central lesions
- TST normal + QSART normal = No significant sudomotor dysfunction
- This combination is the most powerful tool for localizing autonomic lesions to the preganglionic versus postganglionic level
Additional Autonomic Investigations
Skin Biopsy (Epidermal Nerve Fiber Density)
- Principle: 3 mm punch biopsies from standardized sites (typically distal leg 10 cm above lateral malleolus, and proximal thigh); immunostained for PGP 9.5 (pan-axonal marker)
- Measurement: Intraepidermal nerve fiber density (IENFD) — number of nerve fibers crossing the dermal-epidermal junction per mm of epidermis
- Interpretation: Reduced IENFD (below the 5th percentile for age and sex) confirms small fiber neuropathy; the gold standard diagnostic test for SFN
- Clinical utility: Objective confirmation of SFN when NCS/EMG are normal (as expected, since NCS/EMG assess large fibers); abnormal in neuropathic POTS (~50%), diabetic neuropathy, amyloid neuropathy, idiopathic SFN
- Limitations: Does not identify etiology; does not assess autonomic fiber function (only morphology); requires specialized laboratory for processing
Cardiac MIBG Scintigraphy
- Principle: 123I-metaiodobenzylguanidine (MIBG) is a norepinephrine analog taken up by postganglionic sympathetic cardiac nerve terminals; imaging at 15 minutes (early) and 4 hours (late) assesses uptake and retention
- Heart-to-mediastinum ratio (H/M): Quantifies cardiac sympathetic innervation; reduced H/M indicates postganglionic cardiac sympathetic denervation
- Interpretation:
- Reduced uptake (low H/M): PD, DLB, PAF — postganglionic cardiac sympathetic denervation (Lewy body pathology in cardiac nerves)
- Preserved uptake (normal H/M): MSA — preganglionic (central) lesion; cardiac postganglionic neurons are intact
- Clinical utility: Critical for differentiating PD from MSA when the clinical presentation is ambiguous; helpful in predicting phenoconversion in PAF
- Confounders: Medications (tricyclics, SNRIs, labetalol) can reduce MIBG uptake; diabetes with cardiac autonomic neuropathy also reduces uptake
Pupillometry
- Quantitative infrared pupillometry: Measures pupil diameter, constriction velocity, redilation velocity, and latency in response to light stimuli
- Pharmacologic pupil testing: Dilute pilocarpine (0.0625–0.125%) causes constriction in denervated pupils (denervation supersensitivity) but not normal pupils; helps distinguish pre- from postganglionic parasympathetic lesions
- Clinical utility: Tonic (Adie) pupils in AAG; bilateral pupillary dysfunction; Horner syndrome evaluation
Composite Autonomic Severity Score (CASS)
The CASS is a standardized scoring system that integrates results from cardiovagal, adrenergic, and sudomotor testing into a single severity index, facilitating clinical communication, research comparisons, and longitudinal monitoring.
| Domain | Score Range | Tests Used | Score Interpretation |
|---|---|---|---|
| Cardiovagal | 0–3 | HRDB, Valsalva ratio | 0 = normal; 1 = mild; 2 = moderate; 3 = severe cardiovagal failure |
| Adrenergic | 0–4 | Beat-to-beat BP during Valsalva, tilt table BP | 0 = normal; 1 = mild; 2 = moderate; 3 = severe; 4 = adrenergic failure with syncope or presyncope |
| Sudomotor | 0–3 | QSART (4-site) | 0 = normal; 1 = mild (single site); 2 = moderate (2 sites); 3 = severe (3–4 sites or generalized) |
| Total CASS | 0–10 | Sum of all domains | 0 = no autonomic dysfunction; 1–3 = mild; 4–6 = moderate; 7–10 = severe autonomic failure |
Interpretation: Combining Tests to Localize Autonomic Lesions
Central vs Peripheral Autonomic Failure
- Central (preganglionic) lesion — MSA pattern:
- Severe orthostatic hypotension with absent compensatory HR rise
- Absent Valsalva phase II recovery and phase IV overshoot
- Normal or mildly reduced supine plasma NE with failure to rise on standing
- TST abnormal but QSART normal (preganglionic sudomotor pattern)
- Cardiac MIBG preserved (normal H/M ratio)
- Peripheral (postganglionic) lesion — PAF/PD pattern:
- Severe orthostatic hypotension with absent compensatory HR rise
- Absent Valsalva phase II recovery and phase IV overshoot
- Low supine plasma NE (<100 pg/mL) with failure to rise on standing
- TST abnormal AND QSART abnormal (postganglionic pattern)
- Cardiac MIBG reduced (low H/M ratio)
Common Autonomic Diagnoses and Expected Testing Patterns
| Diagnosis | Tilt Table | Valsalva (BP) | HRDB | QSART | TST | Supine NE | MIBG |
|---|---|---|---|---|---|---|---|
| POTS | HR ≥30 bpm rise; no significant OH | Normal or exaggerated HR swings | Normal or mildly reduced | Normal or reduced distally (neuropathic subtype) | Normal or length-dependent | Normal or elevated standing NE (>600 in hyperadrenergic) | Normal |
| PAF | Severe OH; blunted HR | Absent phase II recovery + phase IV | Reduced | Reduced (postganglionic) | Abnormal (postganglionic pattern) | Low (<100) | Reduced |
| MSA | Severe OH; blunted HR | Absent phase II recovery + phase IV | Reduced | Normal or mildly reduced | Abnormal (preganglionic pattern) | Normal or mildly low | Preserved |
| PD with autonomic failure | Moderate–severe OH; blunted HR | Variably abnormal | Reduced | Reduced (postganglionic) | Abnormal (postganglionic pattern) | Low to low-normal | Reduced |
| Diabetic autonomic neuropathy | Moderate OH; some HR response preserved early | Progressive abnormality with severity | Reduced (often earliest finding) | Reduced (length-dependent) | Length-dependent anhidrosis | Variable | Reduced (if severe) |
| AAG (high-titer) | Severe OH; fixed HR | Absent phase II recovery + phase IV | Severely reduced | Reduced (postganglionic pattern) | Global or diffuse anhidrosis | Low (postganglionic effect at ganglia) | Variable |
| Vasovagal syncope | Sudden BP drop ± bradycardia (late in tilt) | Normal | Normal | Normal | Normal | Normal | Normal |
Practical Considerations and Pre-Test Preparation
| Consideration | Details |
|---|---|
| Medication withdrawal | Ideally withhold sympathomimetics (midodrine, droxidopa), anticholinergics, beta-blockers, and fludrocortisone for ≥48 hours (or 5 half-lives) before testing; discuss with referring physician regarding safety |
| Hydration and meals | Patient should be well-hydrated but fasting for ≥3 hours before testing (post-prandial state affects BP responses) |
| Caffeine and nicotine | Avoid for ≥12 hours before testing (both affect autonomic tone and sweat gland function) |
| Environment | Temperature-controlled room (22–25°C); patient should be relaxed and comfortable; anxiety can cause false-positive tachycardia |
| Age and sex norms | All cardiovagal and sudomotor results must be interpreted against age- and sex-matched normative data; autonomic function physiologically declines with aging |
| Comorbidities | Heart failure, atrial fibrillation (invalidates HR-based tests), cardiac pacemaker (limits HR tests), severe peripheral vascular disease (affects finger plethysmography) |
| Skin conditions | Excessive callus or skin lesions at QSART/skin biopsy sites may affect results |
Common Interpretation Errors
- Attributing tilt table tachycardia to POTS without excluding OH: Always verify that BP criteria for OH are not met before diagnosing POTS
- Ignoring medication effects: Many common medications (antihypertensives, antidepressants, anticholinergics) can cause abnormal autonomic testing; always review medication list
- Over-relying on HR-based tests in atrial fibrillation: HR variability metrics are invalid in AF; rely on BP-based measures (Valsalva BP phases, tilt BP response)
- Interpreting Valsalva ratio alone without BP waveform: Valsalva ratio reflects cardiovagal function only; adrenergic interpretation requires beat-to-beat BP during Valsalva
- Failure to use age-matched norms: Autonomic function declines with age; applying young adult norms to elderly patients produces false-positive results
- Misinterpreting initial orthostatic tachycardia: A transient HR spike in the first 30 seconds of standing is physiologically normal and should not be counted toward POTS diagnosis
References
- Low PA. Autonomic nervous system function. J Clin Neurophysiol. 1993;10(1):14-27.
- Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993;68(8):748-752.
- Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1-8.
- Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012;87(12):1196-1201.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Cheshire WP. Thermoregulatory disorders and illness related to heat and cold stress. Auton Neurosci. 2016;196:91-104.
- Novak P. Quantitative autonomic testing. J Vis Exp. 2011;(53):2502.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139-146.
- Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol. 2010;17(7):903-912.
- Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonisms: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18(5):494-500.
- Benarroch EE. The clinical approach to autonomic failure in neurological disorders. Nat Rev Neurol. 2014;10(7):396-407.
- Cheshire WP, Freeman R, Gibbons CH, et al. Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and International Society for Autonomic Neuroscience. Clin Neurophysiol. 2021;132(2):666-682.
- Sandroni P, Benarroch EE, Low PA. Pharmacological dissection of components of the Valsalva maneuver in adrenergic failure. J Appl Physiol. 1991;71(4):1563-1567.
- Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27(12):2942-2947.
- Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018;33(3):349-358.